sickle cell disease

(photo by Erin O. Smith)

Vanderbilt-Ingram researchers present cancer advancements at ASH 2025 

Established in 1958, ASH is the world’s largest professional organization for clinicians and scientists who study blood diseases. 

Michael R. DeBaun, MD, MPH

Vanderbilt’s Michael R. DeBaun elected to American Academy of Arts and Sciences

This year, 247 members were elected from the mathematical, physical, biological, social and behavioral sciences, humanities, the arts, leadership, policy and communications.

(iStock image)

Blood formation and disorders expert Stuart Orkin to present Discovery Lecture March 27

Orkin’s research led to a gene therapy for sickle cell disease and beta-thalassemia; it is the first Food and Drug Administration-approved CRISPR-based gene therapy.

(iStock)

VUMC part of new study validating curative therapy for sickle cell disease

Of 38 adults with severe SCD who participated in the study, more than 97% no longer required immunosuppressive therapy one year after the transplant.

International trial introduces another curative option for sickle cell disease 

The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.

(iStock image)

VUMC hosts symposium on stem cell transplants and cellular therapies

The Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium offers clinicians detailed information on the latest developments for hematological diseases, ranging from immunotherapies for blood cancers to new, curative therapies for sickle cell disease.

1 2